Medicenna Therapeutics Corp (MDNA)

Etorro trading 970x250
Medicenna Therapeutics Corp (MDNA) Logo

About Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Address: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2

Medicenna Therapeutics Corp News and around…

Latest news about Medicenna Therapeutics Corp (MDNA) common stock and company :

Medicenna to Participate in Upcoming January Investor Conferences
05 Jan, 2022 Yahoo! Finance

TORONTO and HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that company management will be participating in the following virtual investor conferences taking place in January 2022. Details are as follows: 11th Annual LifeSci Partners Corporate Access Event (January 5 – 7, 2022)Format: Panel Presentation and 1x1 investor meetings Panel Title: Next Gen Immune-

Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
22 Dec, 2021 Yahoo! Finance

-- Peak CD8+ T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts -- MDNA11-induced increases in CD8+ T and NK cells compare favorably to competing IL-2 variants in the clinic -- No dose limiting toxicity, or any evidence of cytokine release syndrome, nor any evidence of vascular leak syndrome has been observed TORONTO and HOUSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medi

Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada
17 Dec, 2021 Yahoo! Finance

-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data expected by year-end 2021 -- Initial efficacy data update expected in mid-2022 TORONTO and HOUSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Health Canada has

AWM Investment Company, Inc. Buys Destination XL Group Inc, LiqTech International Inc, Gambling. ...
16 Dec, 2021 Yahoo! Finance

New York, NY, based Investment company AWM Investment Company, Inc. (Current Portfolio) buys Destination XL Group Inc, LiqTech International Inc, Gambling.com Group, PLBY Group Inc, Veru Inc, sells , Generation Bio Co, American Public Education Inc, Ondas Holdings Inc, Medicenna Therapeutics Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, AWM Investment Company, Inc..

Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology
18 Nov, 2021 Yahoo! Finance

TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presenta

80 Biggest Movers From Yesterday
17 Nov, 2021 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a ...

53 Stocks Moving In Tuesday's Mid-Day Session
16 Nov, 2021 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 ...

MDNA: Preliminary Update from ABILITY Trial of MDNA11 in Late Calendar 2021…
16 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Phase 1/2 ABILITY Trial Underway; Initial Safety and Biomarker Data by Year-End 2021 Medicenna Therapeutics Corp. (NASDAQ:MDNA) recently initiated the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid tumors. It is designed to assess the safety,

Great news for Medicenna Therapeutics Corp. (TSE:MDNA): Insiders acquired stock in large numbers last year
12 Nov, 2021 Yahoo! Finance

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its ...

Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights
12 Nov, 2021 Yahoo! Finance

-- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022 -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today provided a business update and announced its financial results and operational highlights for the quarter ended September 30, 2

Earnings Scheduled For November 12, 2021
12 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on ...

Medicenna Therapeutics to Present at Stifel’s Virtual Healthcare Conference
09 Nov, 2021 Yahoo! Finance

TORONTO and HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting a corporate overview at Stifel’s Virtual Healthcare Conference on Monday, November 15, 2021. Details are as follows: Event: Stifel Virtual Healthcare Conference Format: Corporate Overview Date: Monday,

Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021
04 Nov, 2021 Yahoo! Finance

TORONTO and HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ET to report its second quarter 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the United States or (201) 493-6779 internationally, followed by the conference I

Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States
27 Oct, 2021 Yahoo! Finance

-- ABILITY Study is currently ongoing at clinical trial sites in Australia -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Initial efficacy data update expected in mid-2022 TORONTO and HOUSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ/TSX: MDNA), a clinical stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared Medicenna’s investigational new d

Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference
07 Oct, 2021 Yahoo! Finance

-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP) -- MDNA11 administration in NHPs did not lead to safety issues typically associated with IL-2 -- MDNA11 alone or in combination with anti-PD1 checkpoint inhibitor resulted in 100% tumor control and long-term protection against tumor re-challenge by inducing antigen-specific CD8 T cells in murine cancer model TORONTO and HOUS

Medicenna Appoints Dr. John H. Sampson to its Board of Directors
23 Sep, 2021 FinancialContent

Announces Results of Annual Meeting of Shareholders

Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit
22 Sep, 2021 FinancialContent
Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit
22 Sep, 2021 Yahoo! Finance

TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Next-Gen Cytokine Therapeutics Summit today. Dr. Fahar Merchant, President and CEO of Medicenna, will deliver a presentation entitled, “Evolutionary IL-2 Superkines: Past, Present and Future” at 2:50 pm EDT. In addition to Dr. Merchant’s pr

Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program
20 Sep, 2021 FinancialContent

Patent covers the use of IL-2 Superkines such as MDNA11 to treat a wide range of specified cancer types

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
14 Sep, 2021 FinancialContent
Medicenna Therapeutics to Present at Upcoming September Investor Conferences
09 Sep, 2021 FinancialContent
MDNA: On Track to Dose First Patient in MDNA11 Phase 1 Trial in 3Q21…
18 Aug, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update CTA Submitted, Phase 1/2 Clinical Trial of MDNA11 to Start in 3Q21 In June 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced it has submitted a Clinical Trial Application (CTA) in Australia in order to initiate the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights
13 Aug, 2021 FinancialContent
Earnings Scheduled For August 13, 2021
13 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021
04 Aug, 2021 FinancialContent

Medicenna Therapeutics Corp (MDNA) is a NASDAQ Common Stock listed in , ,

970x250